INOVIO PHARMACEUTICALS, INC.
INO-3107
Recurrent Respiratory Papillomatosis (RRP)
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews INO-3107 for Recurrent Respiratory Papillomatosis (RRP) around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“The FDA has agreed to a yet-to-be-scheduled meeting to discuss eligibility for review under the accelerated approval program.”